RAN-LISINOPRIL TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Saatavilla:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC-koodi:

C09AA03

INN (Kansainvälinen yleisnimi):

LISINOPRIL

Annos:

20MG

Lääkemuoto:

TABLET

Koostumus:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

Antoreitti:

ORAL

Kpl paketissa:

100/500

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0121550002; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2007-10-17

Valmisteyhteenveto

1
_Pr_
_RAN_
_™_
_-LISINOPRIL (Lisinopril Tablets USP) Product Monograph _
PRODUCT MONOGRAPH
PR
RAN
™
-LISINOPRIL
Lisinopril Tablets USP
Tablets 5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
August 4, 2017
Submission Control Number: 207727
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
2
_Pr_
_RAN_
_™_
_-LISINOPRIL (Lisinopril Tablets USP) Product Monograph _
PRODUCT MONOGRAPH
PR
RAN
TM
-LISINOPRIL
Lisinopril Tablets USP
Tablets 5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in
the treatment of
hypertension, congestive heart failure and following myocardial
infarction in
hemodynamically stable
patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor substance,
angiotensin II. Inhibition of ACE results in decreased plasma
angiotensin II, which
leads to increased
plasma renin activity (due to removal of negative feedback of renin
release)
and decreased aldosterone
secretion. Although the latter decrease is small, it results in a
small
increase in serum potassium. In
patients treated with RAN-LISINOPRIL and a thiazide diuretic there was
essentially no change in serum
potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a potent
vasodilator peptide. However, the role that this plays in the
therapeutic
effects of lisinopril is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be
primarily the
suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
Hypertension
_Adults: _Administration of lisinopril to patients with hypertension
results in a reduction of both supine
and
standing blood pressure. Abrupt withdrawal of l